CHICAGO, July 31, 2025 /PRNewswire/ -- The Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC), welcomed thousands of laboratory experts to ADLM 2025...
TOKYO and CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the two-year real-world study in the U.S of lecanemab (generic name, product name: LEQEBMI®), an anti-Aβ protofibril* antibody, was presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada and virtually. Only lecanemab fights AD in two ways – targeting both amyloid plaque and protofibrils*, which can impact tau downstream.
MOBILE, Ala., July 29, 2025 /PRNewswire/ -- AltaPointe Health is excited to announce the opening of its newest children's outpatient clinic located at 4211...
22nd Century VLN® products are the only combustible cigarettes authorized by the FDA as a reduced nicotine content product that comply with the FDA proposed rule
BATON ROUGE, La., July 29, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month periods ended June 30, 2025.
In this free webinar, learn how advanced autoimmune testing supports diagnostic clarity in early or ambiguous clinical presentations. The featured speakers will review case-based evidence...
LEBANON, Ore., July 24, 2025 /PRNewswire/ -- Western University of Health Sciences' College of Osteopathic Medicine of the Pacific-Northwest will be named the Heatherington...
Commack, NY, July 24, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that its board of directors has approved a bridge funding raise of up to an aggregate amount of $3 million, of which it has secured approximately $1.2 million, through the issuance of shares of the Company’s common stock to institutional or accredited investors.
START enhances its global leadership by integrating Advarra's advanced regulatory and technology solutions, creating a seamlessly connected site network to accelerate trials and relieve...